Drug Profile


Alternative Names: SOR-C13

Latest Information Update: 29 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Soricimed Biopharma
  • Class Antineoplastics; Peptides
  • Mechanism of Action TRPV6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ovarian cancer; Solid tumours

Most Recent Events

  • 27 Sep 2016 SOR C13 receives Orphan Drug status for Pancreatic cancer in USA
  • 19 Jul 2016 Final adverse events and efficacy data from a phase I trial in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 08 Mar 2016 SOR C13 receives Orphan Drug status for Ovarian cancer (Late-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top